BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25542400)

  • 1. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.
    Taylor F; Short D; Winter MC; Tidy J; Savage PM; Sarwar N; Hancock BW; Seckl MJ; Coleman RE
    Gynecol Oncol; 2015 Feb; 136(2):258-63. PubMed ID: 25542400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid.
    Taylor F; Grew T; Everard J; Ellis L; Winter MC; Tidy J; Hancock BW; Coleman RE
    Eur J Cancer; 2013 Oct; 49(15):3184-90. PubMed ID: 23870384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
    Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
    Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia.
    Strohl AE; Lurain JR
    Gynecol Oncol; 2016 May; 141(2):276-280. PubMed ID: 26896825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia.
    Kizaki S; Hashimoto K; Matsui H; Usui H; Shozu M
    Gynecol Oncol; 2015 Dec; 139(3):429-32. PubMed ID: 26456138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
    Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
    Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
    Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
    J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
    McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
    J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
    Mangili G; Cioffi R; Danese S; Frigerio L; Ferrandina G; Cormio G; Rabaiotti E; Scarfone G; Gadducci A; Bergamini A; Pisano C; Candiani M
    Gynecol Oncol; 2018 Dec; 151(3):449-452. PubMed ID: 30266260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
    Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
    J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
    Braga A; Campos V; Filho JR; Lin LH; Sun SY; de Souza CB; da Silva RCAF; Leal EAS; Silveira E; Maestá I; Madi JM; Uberti EH; Viggiano M; Elias KM; Horowitz N; Berkowitz RS
    Gynecol Oncol; 2018 Feb; 148(2):239-246. PubMed ID: 29248195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia].
    Wu XD; Chen LL; Shen T; Chen SS; Chen QQ; Qin JL; Fu YF; Lü WG
    Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(23):1769-1772. PubMed ID: 28647996
    [No Abstract]   [Full Text] [Related]  

  • 19. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
    Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
    J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
    Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.